EVALUATION OF TOTAL MESORECTAL EXCISION WITH OR WITHOUT LATERAL PELVIC LYMPH NODES DISSECTION FOR MIDDLE AND LOWER RECTAL CANCER


Evaluation of Total Mesorectal Excision With or Without Lateral Pelvic Lymph Nodes Dissection for Middle and Lower Rectal Cancer


Mohamed Abdo Etman; Ayman Ahmad Albatanony; Mohammed Sabry Ammar; Mohammed A. Elbalshy

Department of General Surgery, Faculty of Medicine, Menoufia University, Egypt



Background: The most important prognostic factor in colorectal cancer is nodal status, and lymph node metastasis is a determining factor for adjuvant chemotherapy and subsequently key to predicting disease free and overall survival.

Methods: A descriptive prospective study was conducted on 40 patients presenting with middle and low rectal cancer to the outpatient clinic of Menoufia University Hospitals. All patients in the study will require resection of their tumors by total mesorectal excision by open and laparoscopic techniques. Patients will be divided into 2 groups: Group A: was operated without lateral pelvic lymph nodes dissection. Group B: was operated with lateral pelvic lymph nodes dissection during the period between November 2018 and November 2020.

Results: The main presentation of patients was bleeding per rectum 12 (30%), 12 (30%) patients have constipation. 28 patients with adenocarcinoma (70%) and 8 mucinous (20 %) and 4 (10%) with signet ring. Sixteen patients undergo Low ant resection (40%), 16 patients with AP. resection (40 %) and 8 patients with Intersphencteic resection (20%). Regarding intraoperative data, with a mean operative time was (90.00 ± 3.84 min.) for without Lateral pelvic L.N dissection and (122.91±4.89 min.) for with Lateral pelvic L.N dissection.

Conclusion: Surgical mortality of LPLD is low, but there is an increase of morbidities in the form of prolonged operative time, intraoperative blood loss and genito-urinary malfunction. For avoiding the drawbacks of LPLD extended lymphadenectomies with sparing of the pelvic nerves is recommended. Lateral pelvic lymph node involvement is a regional disease that is curable. LPLD was effective to control recurrence at lateral nodes sites.


Keywords: Pelvic Lymph node dissection, Cancer Rectum, Tumor Staging, local recurrence.

Free Full-text PDF


How to cite this article:

Mohamed Abdo Etman; Ayman Ahmad Albatanony; Mohammed Sabry Ammar; Mohammed A. Elbalshy. .Evaluation of Total Mesorectal Excision With or Without Lateral Pelvic Lymph Nodes Dissection for Middle and Lower Rectal Cancer. American Journal of Surgical Research and Reviews, 2021, 4:17. DOI:10.28933/ajsrr-2021-03-2105


References

1. Akiyoshi T, Matsueda K, Hiratsuka M, Unno T, Nagata J, Nagasaki T, Konishi T, Fujimoto Y, Nagayama S, Fukunaga Y, Ueno M. Indications for lateral pelvic lymph node dissection based on magnetic resonance imaging before and after preoperative chemoradiotherapy in patients with advanced low-rectal cancer. Annals of Surgical Oncology. 2015; 22(3):614-20.
2. Allison AS, Bloor C, Faux W, Arumugam P, Widdison A, Lloyd-Davies E, Maskell G. The an-giographic anatomy of the small arteries and their collaterals in colorectal resections: some insights into anastomotic perfusion. Annals of surgery. 2010; 251(6):1092-7.)
3. Arnold M, Sierra MS, Laversanne M, Soerjomata-ram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortali-ty. Gut. 2017; 66(4):683–91.
4. Beck DE, Roberts PL, Saclarides TJ, Senagore AJ, Stamos MJ, Wexner SD, editors. The AS-CRS textbook of colon and rectal surgery. Springer Science & Business Media 2nd ed; New York, 2011.
5. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system, 4th edition. Lyon, France: International Agency for Research on Cancer 2010.
6. Brown G, Kirkham A, Williams GT, Bourne M, Radcliffe AG, Sayman J, Newell R, Sinnatamby C, Heald RJ. High-resolution MRI of the anatomy important in total mesorectal excision of the rec-tum. American journal of roentgenology. 2004; 182(2):431-9.
7. Butte JM, Tang P, Gonen M, et al. Rate of resid-ual disease after complete endoscopic resection of malignant colonic polyp. Dis Colon Rectum 2012; 55:122-7.
8. Canessa CE, Badía F, Fierro S, Fiol V, Háyek G. Anatomic study of the lymph nodes of the mesorectum. Diseases of the colon & rectum. 2001; 44(9):1333-6.
9. Chen JS, Hsieh PS, Chiang JM, et al. Clinical outcome of signet ring cell carcinoma and mu-cinous adenocarcinoma of the colon. Chang Gung Med J 2010; 33:51-7.
10. Cheng J, Chen Y, Wang X, Wang J, Yan Z, Gong G, et al. Meta-analysis of prospective co-hort studies of cigarette smoking and the inci-dence of colon and rectal cancers. Eur J Cancer Prev. 2015; 24(1):6–15.
11. Corman ML, et al. Corman’ colon and rectal sur-gery. 6th rev ed. Philadelphia: Lippincott Williams and Wilkins, 2012.
12. Cress RD, Morris C, Ellison GL, Goodman MT. Secular changes in colorectal cancer incidence by subsite, stage at diagnosis, and race/ethnicity, 1992-2001. Cancer. 2006; 107(5):1142-1152.
13. Dayal S, Nick B, and Tom C. “Evolution of sur-gical treatment for rectal cancer: a review.” Jour-nal of Gastrointestinal Surgery 2017; 21(7): 1166-1173.
14. Dujovny N, Quiros RM, Saclarides TJ. Anorectal anatomy and embryology. Surg Oncol Clin N Am. 2014; 13:277–93.
15. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screen-ing, and treatment) to reduce future rates. Can-cer. 2010; 116(3):544-573.
16. Fazio VW, et al. Current Therapy in Colon and Rectal Surgery E-Book. Elsevier Health Scienc-es, 2016.
17. Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014; 14(5):342–57.
18. Ferlay J, Soerjomataram I, Ervik M. GLOBOCAN 2012 v1.0, cancer incidence and mortality world-wide: IARC cancer base no. 11. Lyon: Interna-tional Agency for Research on Cancer; 2013.
19. Fields AC, et al. “Oncologic outcomes for low rectal adenocarcinoma following low anterior re-section with coloanal anastomosis versus ab-dominoperineal resection: a National Cancer Da-tabase propensity matched analysis.” Interna-tional journal of colorectal disease 2019; 1-6.
20. Fleming M, et al. “Colorectal carcinoma: patho-logic aspects.” Journal of gastrointestinal on-cology 2012; 3(3): 153.
21. Fleming M, et al. “Colorectal carcinoma: patho-logic aspects.” Journal of gastrointestinal on-cology 2012; 3(3): 153.
22. Fujita S, Akasu T, Mizusawa J, Saito N, Kinu-gasa Y, Kanemitsu Y, Ohue M, Fujii S, Shiozawa M, Yamaguchi T, Moriya Y. Postoperative mor-bidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, random-ised controlled, non-inferiority trial. The Lancet Oncology. 2012; 13(6):616-21.
23. Fujita S, Mizusawa J, Kanemitsu Y, Ito M, Kinu-gasaY, Komori K, et al. Mesorectal excision with or without lateral lymph node dissection for clini-cal stage II/ III lower rectal cancer (JCOG0212): a multicenter,randomized controlled, noninferiority trial. Ann Surg. 2017; 266(2):201–7.
24. Fujita S, Nakanisi Y, Taniguchi H, Yamamoto S, Akasu T, Moriya Y, Shimoda T. Cancer invasion to Auerbach’s plexus is an important prognostic factor in patients with pT3-pT4 colorectal cancer. Diseases of the colon & rectum. 2003; 50(11):1860-6.
25. Fujita S, Yamamoto S, Akasu T. Risk factors of lateral pelvic lymph node metastasis in ad-vanced rectal cancer. Int J Colorectal Dis. 2009; 24:1085–90.


Terms of Use/Privacy Policy/ Disclaimer/ Other Policies:
You agree that by using our site, you have read, understood, and agreed to be bound by all of our terms of use/privacy policy/ disclaimer/ other policies (click here for details).



This work and its PDF file(s) are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.